Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection

Annals of Pharmacotherapy

Volumn 42, Issue 2, 2008, Pages 185-191

  Cat, Tram B ^a   Charash, William ^b   Hebert, James ^b   Marden, Brian T ^c   Corbett, Stephanie Mallow ^d   Ahern, John ^e   Rebuck, Jill A ^f  

^a Antelope Valley Hospital   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e FLETCHER ALLEN HEALTH CARE   (United States)

^f LANCASTER GENERAL HOSPITAL   (United States)

Author keywords

Antisecretory therapy; Candida; Gastric acid suppression; Histamine antagonist; Intraabdominal infection; Proton pump inhibitor; Yeast

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STOMACH SECRETION INHIBITOR;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ADULT; AGED; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDIASIS; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION COMPLICATION; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION;

ABDOMEN; AGED; CANDIDA; CANDIDIASIS; CASE-CONTROL STUDIES; CROSS INFECTION; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 39049147707     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K328     Document Type: Article

References (30)

1. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003;31:2228-37.
2. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections. Clin Infect Dis 2003;37:997-1005.
3. Wittmann DH, Schein M, Condon RE. Management of Secondary Peritonitis. Ann Surg 1996;224:10-8.
4. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998;22:158-63.
5. Rex JH, Sobel JD. Preventing intra-abdominal candidiasis in surgical patients. Crit Care Med 1999;27:1033-4.
6. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004;32:2008-13.
7. 2 receptor antagonist in critically ill trauma patients? Curr Surg 2004;61:452-8.
8. Laheij RJF, Sturkenboom MCJM, Hassing RJ, Dieleman J, Strieker BHC, Jansen JBMJ. Risk of community-acquired pneumonia and use of gastric acid-suppressive drags. JAMA 2004;292:1955-60.
9. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch Intern Med 2007;167:950-5.
10. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-as sociated disease. JAMA 2005;294:2989-95.
11. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 2003;54:243-5.
12. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8.
13. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile- associated disease in nursing home patients. J Am Med Dir Assoc 2005;6:105-8.
14. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment Pharmacol Ther 2006;24:613-9.
15. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166:2518-24.
16. Rousseau MC, Catala A, Blaya J. Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for a long duration. Brain Injury 2003;17:883-7.
17. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68.
18. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001;15:511-21.
19. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 1996;39:54-9.
20. 2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology 2004;51:1540-3.
21. Shindo K, Machida M, Fukumura M, Koide K, Yamazaki R. Omeprazole induces altered bile acid metabolism. Gut 1998;42:266-71.
22. Gianella RA, Broitman SA, Zamcheck N. Salmonella enteritis. I. Role of reduced gastric secretion in pathogenesis. Am J Dig Dis 1971;16:1000-6.
23. Gianella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 1973;78:271-6.
24. Laheij RJF, Van Ijzendoorn MC, Janssen MJR, Jansen JBMJ. Gastric acid-suppressive therapy and community acquired respiratory infections. Aliment Pharmacol Ther 2003;18:847-51.
25. Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Fungal colonization of gastric mucosa and its clinical relevance. Med Sci Monit 2001;7:982-8.
26. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-6.
27. Yeomans ND, Brimblecombe RW, Elder J, et al. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995;40(suppl):S81-95.
28. Gray JDA, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut 1967;8:574-81.
29. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: evidence for the recommendations. Surg Infect 2002;3:175-233.
30. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003;16:533-7.